Wondering how the International IgAN Prediction Tool developed by @IIgANN_Research can be used to enrich clinical trial cohorts? We address this here in KI Reports.
kireports.org/article/S2468-…
English
Sean Barbour
106 posts
Sean Barbour
@SeanJBarbour
Clinical Associate Professor, Division of Nephrology, University of British Columbia Chair, BC Glomerulonephritis Committee and Network, BC Renal
Katılım Nisan 2019
72 Takip Edilen357 Takipçiler
Sean Barbour retweetledi
Happy to see this article published. @SeanJBarbour and I discuss the latest in IgAN therapy. It’s an exciting time in a disease where the bar is high to prevent kidney failure.
SevenOaksCDIC@SevenOaksCDIC
In their recent review article, Drs. @BryceBarr9 & @SeanJBarbour provide an overview of the newest therapeutic options, including disease-modifying & nephroprotective drugs, that are available for people living with IgA nephropathy. ➡️ bit.ly/3v40QUU
English
Sean Barbour retweetledi
A new study shows that people with glomerulonephritis (GN) are at significantly higher risk of experiencing active tuberculosis (TB) infections, at a rate 23 times higher than the general population. Read our story: ow.ly/Vzv450QcJ6b #KidneyResearch #GN #TB @UBCmedicine
English
Sean Barbour retweetledi
Congratulations to Prof Adeera Levin for the Jean Hamburger Award which recognizes outstanding research in nephrology with a clinical emphasis.
The award will be bestowed at the #ISNWCN 2024, in April 2024, at Buenos Aires, Argentina. #jeanAward" target="_blank" rel="nofollow noopener">theisn.org/blog/2023/12/1…
English
Sean Barbour retweetledi
Incidence of and Risk Factors for Active Tuberculosis Disease in Individuals With Glomerular Disease: A Canadian Cohort Study
buff.ly/40WaIvG
@MarkCanney @HMGunning @SeanJBarbour @OttawaRenal @UBCNephrology
English
Sean Barbour retweetledi
KDIGO guidelines recommend anti-PLA2R antibody levels as a marker of treatment response in membranous nephropathy. This Podcast discusses findings that anti-PLA2R antibody levels with albumin levels after 3 months of treatment was the optimal method bit.ly/CPOD0237
English
lww.com/_layouts/15/oa…
Based on data from the MENTOR trial, you can use changes in clinical data and PLA2R Ab levels to predict treatment response to CsA or rituximab in MN. Listen to the podcast summary for more details.
English
Sean Barbour retweetledi
Happy July! Episode just released on IgAN- adult vs. pediatric perspectives with GN experts @SeanJBarbour and @AlexandraCambi4 New nephrology fellows- welcome 👏and use this podcast as a go-to resource😀 open.spotify.com/episode/5JTg2O… @ASNKidney @goKDIGO @RenalFellowNtwk @ASPNeph
English
Sean Barbour retweetledi
@MattGosseMD @IHC_guy @ChangUCanSpare @SethiRenalPath @JZRenalPath Right now we only do it by IF but we will be looking into IHC as well!
English
Sean Barbour retweetledi
#StatsTwitter anyone noticed a huge double standard with respect to stats vs lab methods? Stats methods said to be "confusing" with request to "do something simpler" on papers where complex lab methods are inscrutable to anyone but a hard core expert in that narrow lab field?
English
Great resource for people in BC with glomerular diseases!
BC Renal@BCRenal
About 6,000 British Columbians live with glomerulonephritis (GN). Now @BCRenal has a web page aimed at addressing their needs. Read more about this "made in BC" resource: ow.ly/YVP550LsrqF #KidneyPatients #KidneyHealt @PHSAofBC @KidneyBCY
English
Sean Barbour retweetledi
@kidneydoc101 Thanks @kidneydoc101
That’s exactly right - being able to quantify this potential risk and put it in some context
An amazing team worked on this study
@SeanJBarbour has created a fantastic GN data infrastructure in @BCRenal
English
Thread 13
Mark Canney@MarkCanney
The full results are in the manuscript located here jasn.asnjournals.org/content/early/… Thanks to @SeanJBarbour for leading And @acunningMD @stevenhawken @Atiq_M_Zaman Lee Er, Yinshan Zhao and Sophia Zheng for collaborating on this important project @UBCNephrology @BCRenal @OttawaRenal 13/
English